跳至主要内容
临床试验/NCT04987918
NCT04987918Unknown不适用

Gazelle COVID-19 Test Clinical Accuracy Protocol

Hemex Health1 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2021年8月20日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
1,500
试验地点
1
主要终点
Positive percent agreement and negative percent agreement of the Gazelle COVID-19 Test compared to Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) will be measured

研究概览

简要总结

Gazelle COVID-19 is a fluorescent lateral flow immunoassay and accompanying Reader intended for the qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset. The study will be conducted To obtain data to measure the positive percent agreement and negative percent agreement of the Gazelle COVID-19 Test compared to Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).The study will assess Gazelle COVID-19 Test performance using dual mid-turbinate nasal swab samples. This study will primarily assess Gazelle COVID-19 Test performance on symptomatic subjects (within five days of onset of symptoms) at point of care (POC). A subset of asymptomatic subjects will be enrolled after the symptomatic subject enrollment is complete.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • The presence of clinical signs and symptoms consistent with COVID-
  • Signs and symptoms include:
  • Shortness of breath
  • Recent loss of sense of smell or taste
  • Repeated shaking with chills
  • Muscle pain
  • Sore throat
  • Vomiting or diarrhea
  • Within 1-5 days of symptom onset
  • Informed consent for all the samples will be obtained from the subject or obtained from the parent/guardian in case the patient is a minor
  • All genders
  • Pregnant women

排除标准

  • Severe disease requiring immediate medical intervention
  • Inability to tolerate sampling procedure (nasal swab)
  • Failure to provide informed consent
  • Nasal deformities preventing sampling by swab
  • Ongoing nosebleeds or use of a nasal spray within the last 4 hours.
  • Asymptomatic patients
  • Asymptomatic study:
  • Inclusion criteria:
  • Present to the facility for a COVID-19 test without symptoms
  • Informed consent for all specimens will be obtained from the patient or obtained from the parent/guardian in case the patient is a minor
  • Exclusion Criteria:
  • Exclusion criteria include one or more of the following:
  • Severe disease requiring immediate medical intervention
  • Inability to tolerate sampling procedure
  • Is below 2 years old
  • Failure to provide informed consent
  • Nasal deformities preventing sampling by swab
  • Ongoing nosebleeds or use of a nasal spray within the last 4 hours.
  • Presence of typical symptoms of COVID-19 (fever, sore throat, fatigue, etc.)

结局指标

主要结局

Positive percent agreement and negative percent agreement of the Gazelle COVID-19 Test compared to Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) will be measured

时间窗: 3 months

次要结局

  • Sensitivity and specificity on at least 30, maximum 65, SARS-CoV-2 positive patient samples will be assessed(6 months)

研究者

发起方
Hemex Health
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验